Literature DB >> 2386768

Morphologic, immunologic and cytogenetic studies in erythroleukaemia: evidence for multilineage involvement and identification of two distinct cytogenetic-clinicopathological types.

A Cuneo1, A Van Orshoven, J L Michaux, M Boogaerts, A Louwagie, C Doyen, P Dal Cin, F Fagioli, G Castoldi, H Van den Berghe.   

Abstract

Clinical features, as well as morphology, immunophenotype and cytogenetics were retrospectively studied in 20 patients with an original diagnosis of erythroleukaemia (EL) reclassified according to the FAB criteria. Fifteen patients had de novo EL, five patients had therapy-related EL. Myelodysplasia preceded the onset of EL in eight cases and myelodysplastic features involving multiple haemopoietic lineages were observed at leukaemia presentation in all cases. Immunologic findings confirmed multilineage involvement, showing sub-population of cells expressing platelet-associated markers in more than 50% of cases tested and the presence of a myelomonocytic component, besides glycophorin A-positive cells. Cytogenetically, major karyotype aberrations (MAKA), defined by the presence of three or more aberrant events in the same clone, were observed in 14 cases, minor karyotype aberrations (MIKA) were observed in four cases and normal karyotype in two cases. No differences in the cytological-cytogenetic picture of our patients with de novo EL, and with therapy-related EL were found suggesting that aetiological factors and/or pathogenetic mechanisms common to EL and secondary leukaemia may exist. All patients with MAKA had leftward shift of erythropoiesis with proerythroblasts and basophilic erythroblasts usually representing more than 50% of all erythroid cells. In patients with MIKA or normal karyotype, maturatio of erythroid cells, though morphologically abnormal, was quantitatively preserved and early erythroblasts never exceeded 25% of erythroid cells. Clinically, the haemoglobin level at presentation, as well as in the proportion of patients achieving complete remission after chemotherapy, appeared to be lower in the maturation arrest-MAKA group as compared to the preserved maturation-MIKA/normal karyotype group. Median survival was shorter in the former group (3.5 months) than in the latter (median 13 months). Morphologic-immunologic-cytogenetic studies thus allow for the identification of two distinct cytogenetic-clinicopathological types of EL.

Entities:  

Mesh:

Year:  1990        PMID: 2386768     DOI: 10.1111/j.1365-2141.1990.tb04347.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Erythroleukaemia in the north of England: a population based study.

Authors:  A W Wells; N Bown; M M Reid; P J Hamilton; G H Jackson; P R Taylor
Journal:  J Clin Pathol       Date:  2001-08       Impact factor: 3.411

2.  Pure Erythroleukemia (Variant Acute Myeloid Leukemia-vAML-M6) with Deletion of Chromosome 20, Mainly Presenting as Late Erythroblasts, a Unique Case Report with Review of Literature.

Authors:  Javid Rasool; Sajad Geelani; Mohd Suhail Lone; Mohd Shaban
Journal:  Indian J Hematol Blood Transfus       Date:  2012-08-05       Impact factor: 0.900

3.  Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes.

Authors:  Xavier Calvo; Leonor Arenillas; Elisa Luño; Leonor Senent; Montserrat Arnan; Fernando Ramos; María Teresa Ardanaz; Carme Pedro; Mar Tormo; Julia Montoro; María Díez-Campelo; Beatriz Arrizabalaga; Blanca Xicoy; Santiago Bonanad; Andrés Jerez; Benet Nomdedeu; Ana Ferrer; Guillermo F Sanz; Lourdes Florensa
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

4.  Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution.

Authors:  F P S Santos; S Faderl; G Garcia-Manero; C Koller; M Beran; S O'Brien; S Pierce; E J Freireich; X Huang; G Borthakur; C Bueso-Ramos; M de Lima; M Keating; J Cortes; H Kantarjian; F Ravandi
Journal:  Leukemia       Date:  2009-09-10       Impact factor: 11.528

5.  [Erythroblastic acute leukemia: report of seven cases].

Authors:  Imane Tlamçani; Salma Benjelloun; Ghita Yahyaoui; Moncef Hassani Amrani
Journal:  Pan Afr Med J       Date:  2014-05-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.